Featured Articles

Phototherapy for Psoriasis: A Safe and Effective Treatment Modality

By May 12, 2020May 20th, 2020No Comments

Dermatology News

Featured Article

“Fewer people are doing mainstay full-body phototherapy as in the past, as biologics and other systemic therapies have proven to be safe and much more effective,” Dr. Nestor said in a recent interview with Dermatology Times.

Read Article Now

Phototherapy for Psoriasis: A Safe and Effective Treatment Modality

A study recently published in the JDD reveals phototherapy remains a safe and effective treatment modality for mild to moderate psoriasis vulgaris

Phototherapy remains a safe and effective treatment modality for mild to moderate psoriasis, according to Mark S. Nestor, M.D., Ph.D., in a study recently published in the Journal of Drugs in Dermatology.
Current options for treating psoriasis include systemic and topical agents: systemic treatment options may involve immune inhibitors, and/or immune modulators. For moderate to severe cases, biologic agents may be used.
Topical agents may be comprised of ointments, medicated baths, and phototherapy.

“Fewer people are doing mainstay full-body phototherapy as in the past, as biologics and other systemic therapies have proven to be safe and much more effective,” Dr. Nestor said in a recent interview with Dermatology Times.

“Additionally,” he added, “laser has largely taken over for individual and spot treatment of specific areas because you don’t have the same issue of systemic problems with burning.”

In the study, “Randomized, Investigator-Blinded Study to Compare the Efficacy and Tolerance of a 650-microsecond, 1064-nm YAG Laser to a 308-nm Excimer Laser for the Treatment of Mild to Moderate Psoriasis Vulgaris,” co-authored by Dr. Nestor, Daniel Fischer DO MS,a and David Arnold DOa eligible subjects enrolled in a randomized, investigator-blinded study.

Psoriatic plaques on one side of the body were treated with the 650-microsecond laser and plaques on the other side were treated with the 308-nm excimer laser. Study subjects received up to 15 treatments, twice weekly, or fewer if full clearance was achieved. Efficacy and tolerance were evaluated by the mPASI scores and local skin reactions, respectively.

Both devices showed efficacy in treating psoriatic plaques. Differences between the two devices were not significant for redness, thickness, scaliness, mPASI scores for arms and legs, and overall mPASI scores for the treated psoriatic plaques on each side of the body. The investigator-assessed scores for erosion/ulceration, vesicles, erythema, scaling, edema, and atrophy were low and identical for both sides of the body.

“There is potential for utilizing this therapy much more in the future, especially in areas such as the palms and soles, where excimer appears to be less effective,” Dr. Nestor said.

Read Article Now

You May Also Like

Journal of Drugs in Dermatology JDD featuring Dr. Jacob Beer in JDD Re:View, a discussion of JDD articles and specific topics. This article highlights Melanoma on the Rise: Are We Keeping Pace With Detection and Care?Featured ArticlesJDD Re:ViewLatest NewsSkin CancerJDD Re:View With Dr. Beer
June 18, 2026

JDD Re:View With Dr. Beer

JDD Re:View: Recent Advances in Acne and Rosacea Management Melanoma, particularly cutaneous melanoma, is becoming an increasingly prevalent problem in the United States (US). It is currently the fifth most…
Journal of Drugs in Dermatology JDD featuring Predicting Benefit of Adjuvant Radiation Therapy for Cutaneous Squamous Cell Carcinoma: A Systematic ReviewAestheticsFeatured ArticlesLatest NewsOncodermatologySkin CancerPredicting Benefit of Adjuvant Radiation Therapy for Cutaneous Squamous Cell Carcinoma: A Systematic Review
June 17, 2026

Predicting Benefit of Adjuvant Radiation Therapy for Cutaneous Squamous Cell Carcinoma: A Systematic Review

New Review Highlights How Dermatologists May Better Identify cSCC Patients Who Benefit From Adjuvant Radiation Have you read this article from the JDD? A new systematic review is drawing attention to…
Atopic DermatitisFeatured ArticlesLatest NewsNP/PA EducationDual Therapy for Atopic Dermatitis: Lebrikizumab and JAK Inhibitors Used in Tandem for Treatment-Resistant Cases
June 16, 2026

Dual Therapy for Atopic Dermatitis: Lebrikizumab and JAK Inhibitors Used in Tandem for Treatment-Resistant Cases

Promising efficacy and tolerability in this small cohort of patients with treatment-resistant AD Dual Therapy for Atopic Dermatitis: Lebrikizumab and JAK Inhibitors Used in Tandem for Treatment-Resistant Cases from the…

Leave a Reply